Platform trials streamline ALS therapy evaluation by rapidly ruling out ineffective drugs
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
Hosted on MSN1d
Four regimens fail endpoints simultaneously in HEALEY ALS trial
ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the US-wide platform trial.
pharmaphorum2d
Four more drugs in keenly watched ALS trial miss the mark
Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...
Medpage Today on MSN3d
Two Investigational Treatments for ALS Show Glimmer of Hope
The first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...
Science Media Centre3d
expert reaction to four papers trialling treatments for ALS within the HEALEY ALS Platform Trial
Four papers published in JAMA, JAMA Neurology and JAMA Network Open look at Amyotrophic Lateral Sclerosis (ALS) treatment results from the HEALY ALS Platform Trial. Dr Ahmad Al Khleifat, Senior ...
Daily6h
Verdiperstat use may not impact progression of amyotrophic lateral sclerosis: JAMA
A new study published in the recent issue of Journal of American Medical Association found that the usage of verdiperstat, a ...
Accelerated drug-testing platform for ALS paves way for therapeutic innovation
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.
News Medical on MSN3d
Groundbreaking ALS platform trial accelerates research and drug testing
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...
Healio16d
IV edaravone may slow disease-progression milestones in ALS
Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone treatment, results of an administrative claims analysis show."Since ALS has ...
pharmaphorum3d
Denali slides after ALS drug flunks clinical test
Denali Therapeutics' experimental drug for amyotrophic lateral sclerosis (ALS) failed to show efficacy in part of the phase 2/3 HEALEY ALS basket trial, causing a fall in its share price.